Sanofi

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Paris, France
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Alexandra Roger, Alexandra Roger, Head of Legal Corporate & Finance
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Sanofi

Form 4 holding 10%+ Owner

Translate Bio, Inc.

Security class
Common Stock, par value $0.001 per share
Shares / value
75,668,031
Estimated value
$2,875,385,178
Report date
14 Sep 2021
Price
$38.00
Ownership
Direct
Form 4 holding 10%+ Owner

MeiraGTx Holdings plc

Security class
Ordinary Shares ($0.00003881 par value per share)
Shares / value
11,500,000
Estimated value
$73,140,000
Report date
12 Aug 2024
Price
$6.36
Ownership
Through its wholly-owned subsidiary, Sanofi Foreign Participations B.V.
Form 4 holding 10%+ Owner

Icosavax, Inc.

Security class
Common Stock (par value, $0.0001)
Shares / value
3,155,169
Estimated value
$49,449,386
Report date
02 Aug 2021
Price
$15.67
Ownership
Through its wholly-owned subsidiary, Aventis Inc.
Form 4 holding 10%+ Owner

MeiraGTx Holdings plc

Security class
Ordinary Shares ($0.00003881 par value per share)
Shares / value
697,737
Estimated value
$4,437,607
Report date
12 Aug 2024
Price
$6.36
Ownership
Through its wholly-owned subsidiary Kadmon Corporation, LLC
Form 4 holding 10%+ Owner

Icosavax, Inc.

Security class
Series A-1 Preferred Stock (par value, $0.0001)
Shares / value
0
Estimated value
Report date
02 Aug 2021
Price
Ownership
Through its wholly-owned subsidiary, Aventis Inc
Underlying class
Common Stock
Underlying amount
Form 4 holding 10%+ Owner

Icosavax, Inc.

Security class
Series B-1 Preferred Stock (par value, $0.0001)
Shares / value
0
Estimated value
Report date
02 Aug 2021
Price
Ownership
Through its wholly-owned subsidiary, Aventis Inc
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Sanofi

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .